Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation

NCT05491226 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

35

Enrollment

OTHER

Sponsor class

Conditions

TNBC - Triple-Negative Breast Cancer
Breast Cancer

Interventions

DRUG: Pembrolizumab
RADIATION: Radiation Therapy
DRUG: Axatilimab

Sponsor

Stephen Shiao

Collaborators

[object Object]
[object Object]